Advertisement
Advertisement

  

HIV JournalView



  • Top 10 HIV Clinical Developments of 2008 (February 27, 2009)
    David Wohl, M.D., discusses earlier treatment initiation; key studies examining cardiovascular risk and abacavir; inflammatory biomarkers, coagulation biomarkers and mortality; and initial antiretroviral choices and how critical some of our newer medications are to the survival of patients with multidrug resistance.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (June 2008)
    David Wohl, M.D., discusses the real-world clinical impact of studies on: a new treatment for visceral fat accumulation; the rise and fall of abacavir; the latest twist in the HAART/heart saga; HAART's ability to improve renal function; similarities among genotypic resistance algorithms; the virologic impact of baseline NNRTI resistance; and the efficacy of "supersized" hepatitis B revaccination.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 HIV Clinical Developments of 2007 (March 2008)
    How are the landmark studies of 2007 likely to impact your clinical practice? If it's incisive analysis you seek, look no further than David Wohl, M.D.'s overview of the Top 10 HIV Clinical Developments of 2007. With his expert eye and trademark wit, Dr. Wohl takes you behind the data for an up-close look at what the numbers really mean.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (October/November 2007)
    Breaking research on malignancies, metabolic complications, darunavir resistance, sperm washing and more -- concise analysis from David Wohl, M.D.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (September 2007)
    Among other reviews this month, David Wohl, M.D., looks at the latest studies on entecavir and HIV drug resistance and examines how saturated fat intake contributes to HIV-associated hypertriglyceridemia.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (July 2007)
    Among other stories this month, Graeme Moyle, M.D., reviews the potential for shifting HIV tropism and what this means to the use of CCR5 antagonists.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 HIV Medical Stories of 2006 (February 2007)
    It's one of the most insightful, entertaining, informative HIV research recaps you'll read this year: The Body PRO's David Wohl, M.D., presents an end-of-year review of the developments that made the biggest waves among HIV health care professionals in 2006. If you're looking for an easy-to-digest recap of the most critical news in HIV over the last calendar year, this is the article to read.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (September/October 2006)
    Pablo Tebas, M.D., analyzes recently published research on: the utility (or lack thereof) of viral load tests in predicting the rate of CD4+ cell decline; the tendency for HIV-infected patients to have a poorer prognosis when diagnosed with lung cancer than their HIV-uninfected counterparts; the potential for drug interactions between enfuvirtide and ritonavir-boosted tipranavir; and the high prevalence of human papillomavirus infection among sexually active men.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (May/June 2006)
    David Wohl, M.D., examines published research on the quantifiable benefits of HIV care; predicting response to atazanavir/ritonavir; the need for baseline resistance testing; widespread belief in HIV conspiracy theories; adherence and risk-reduction interventions; and recent patterns in body fat changes among HAART patients.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (February/March 2006)
    David Wohl, M.D., analyzes a head-to-head comparison of tenofovir + emtricitabine + efavirenz versus zidovudine/lamivudine + efavirenz in treatment-naive patients; the relationship between antiretroviral class, adherence and resistance; the successes and limitations of HAART in the developing world; and mixed news on investigational enfuvirtide administrations (good news on needle-free administration; bad news on once-daily dosing).
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 Research Publications in HIV Care of 2005 (January 2006)
    Thousands of HIV-related studies were published in 2005, but only a handful heralded fundamental changes in the way we approach HIV screening and treatment; David Wohl, M.D., recaps these critical studies and explains their significance in this issue of HIV JournalView.
    To read PDF, click here.
    From TheBodyPRO.com
  • HIV JournalView (December 2005)
    Mark Holodniy, M.D., discusses recently published studies on partial HIV treatment interruption, lopinavir/ritonavir monotherapy, hyperlipidemia management strategies, coadministration of didanosine + tenofovir, the success of treatment access programs in the developing world, and the protective benefits of male circumcision.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (November 2005)
    Margaret Hoffman-Terry, M.D., analyses the findings of recently published studies on the relationship (or lack thereof) between lipoatrophy and lipohypertrophy, shedding of nevirapine-resistant virus in breast milk, neuropsychiatric impairment in HIV/hepatitis C-coinfected patients, and the importance of using CD4+ cell percentage in treatment initiation decisions.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (September 2005)
    David Wohl, M.D., reviews recently published research on the need (or lack thereof) to switch regimens in patients with low-level viremia, a dementia test for resource-poor areas, the growing epidemic of obesity among HIV-infected patients, the link between insulin resistance and NRTIs (not PIs!), and a final word on the whole valproic acid/"HIV cure" kerfuffle.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (July/August 2005)
    David Wohl, M.D., reviews many newly published studies, including research on the role of HAART in hypertension, the interaction between efavirenz (EFV, Sustiva, Stocrin) and statins, the best way to manage dyslipidemia in HAART patients, and several new approaches to HIV therapeutics.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (May/June 2005)
    Margaret Hoffman-Terry, M.D., examines recent studies on a range of HIV-related health problems, including bone and joint problems, the long-term health risks of tenofovir (TDF, Viread), the neurological effects of efavirenz (EFV, Sustiva, Stocrin) and new insight into the treatment of people who are coinfected with HIV and hepatitis C.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (April 2005)
    Mark Holodniy, M.D., analyzes recently published research on poly-L-lactic acid for facial wasting, resistance testing, interactions between antiretrovirals and natural health products, and several other topical issues in HIV disease management.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (February/March 2005)
    David Wohl, M.D., assesses the significance of recent research on predictors of HIV drug resistance, cost-effectiveness of HIV screening, contraindication of fosamprenavir lopinavir/ritonavir, incidence of NNRTI-related rash and an update on metabolic complications.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 Research Reports of 2004 (January 2005)
    David Wohl, M.D., reviews the top 10 published research reports of 2004.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (December 2004)
    Ben Young, M.D., Ph.D., analyzes a bevy of recently published studies and opinions on HIV treatment; among the topics he examines are when to start treatment, when to pause it and how effective it is on both edges of the age spectrum -- infants and patients over 50; also included is an examination of hepatitis A vaccination in HIV-infected patients.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (October/November 2004)
    David Wohl, M.D., reviews a quintet of recently published studies on mortality, HIV treatment initiation, the tenofovir-associated K65R mutation, viral loads and sexual risk behavior, and cesarean delivery in HIV/hepatitis C-coinfected patients.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com

  • < Previous | 1 | 2 | 3 | Next >


  
Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.